{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T16:58:55Z","timestamp":1715965135243},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s30345","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T00:28:49Z","timestamp":1377822529000},"page":"929","source":"Crossref","is-referenced-by-count":2,"title":["Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis"],"prefix":"10.2147","author":[{"given":"Heather","family":"Elphick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"O'Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2013,8]]},"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=17328","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T18:32:49Z","timestamp":1477852369000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/development-clinical-utility-and-place-of-ivacaftor-in-the-treatment-o-peer-reviewed-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/dddt.s30345","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}